Adverse events · people with burn wounds likely to develop hypertrophic scarring
1 finding from 1 review
Adverse events · Patients aged above 12 years with self-reported tooth hypersensitivity confirmed on clinical evaluation
2 findings from 1 review
Adverse events · people with single or solitary brain metastasis
It is very uncertain whether surgery plus whole brain radiotherapy (WBRT) changes adverse events compared with stereotactic radiosurgery (very low certainty).
1 finding from 1 review
Adverse events · patients with adhesive capsulitis (frozen shoulder)
1 finding from 1 review
Major adverse events · women with POP
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Major adverse events · women with POP
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Major adverse events · women with POP
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Major adverse events · women with POP
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events ‐ matting ( · people with telangiectasias and reticular veins
Sclerotherapy (polidocanol) showed no clear difference in adverse events ‐ matting ( compared with sclerotherapy (any sclerosant) (moderate certainty).
1 finding from 1 review
Anxiety (adverse effect, post‐intervention) · schizophrenia or related disorders
1 finding from 1 review
Adverse events: psychological disorders · children with nephrotic syndrome
Steroid therapy in first episode of nephrotic syndrome: 3 months or… showed no clear difference in adverse events: psychological disorders compared with 2 months of therapy (low certainty).
1 finding from 1 review
Total adverse events · Patients with active mild to moderate ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · physically‐active adults partaking in exercise designed to produce delayed onset muscle soreness (most trial participants were male)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · participants with chronic prostatitis/chronic pelvic pain syndrome
Antibiotic therapy showed no clear difference in adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Specific adverse events: haemorrhage · women with recurrent or FIGO stage IVB cervical cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · carpal tunnel syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events ‐ matting ( · people with telangiectasias and reticular veins
Sclerotherapy plus compression showed no clear difference in adverse events ‐ matting ( compared with sclerotherapy alone (low certainty).
1 finding from 1 review
Adverse events (grade ≥ 3) · people with newly diagnosed multiple myeloma ineligible for transplant
Summary of findings table ‐ Daratumumab plus standard therapy showed no clear difference in adverse events (CTCAE grade ≥ 3) (longest available compared with standard therapy (moderate certainty).
1 finding from 1 review
Serious adverse events and liver‐related morbidity: incidence of gastric varices · primary prophylaxis of oesophageal variceal bleeding in children with chronic liver disease or portal vein thrombosis
It is very uncertain whether sclerotherapy changes serious adverse events and liver‐related morbidity: incidence of… compared with no intervention (very low certainty).
1 finding from 1 review
Serious adverse events · people with chronic lymphocytic leukaemia
Anti‐leukaemic therapy plus alemtuzumab showed no clear difference in serious adverse events compared with anti‐leukaemic therapy alone (anti‐leukaemic therapy identical (moderate certainty).
1 finding from 1 review